ValuEngine upgraded shares of Cesca Therapeutics Inc. (NASDAQ:KOOL) from a sell rating to a hold rating in a research report released on Tuesday.
Separately, Maxim Group reaffirmed a hold rating on shares of Cesca Therapeutics in a research note on Friday, May 12th.
Cesca Therapeutics (NASDAQ KOOL) traded up 2.27% on Tuesday, hitting $3.60. The company had a trading volume of 20,037 shares. Cesca Therapeutics has a one year low of $2.41 and a one year high of $7.39. The stock’s 50-day moving average price is $3.08 and its 200 day moving average price is $3.05. The company’s market capitalization is $35.65 million.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2723585/cesca-therapeutics-inc-nasdaqkool-upgraded-to-hold-by-valuengine.html.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cesca Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.